GlaxoSmithKline
Multinational drug firm, GSK, quits Kenya four months after Nigeria’s
GlaxoSmithKline (GSK), a British pharmaceutical multi-national, has closed its operations in Kenya, four months after exiting Nigeria in what appears to be global restructuring plan of its business model.
The company has operated a manufacturing facility in Kenya for nearly six decades and will now rely on distributors to supply its products to the regional markets. GSK has attributed its exit to low sales and a shift in focus to its more profitable prescription drugs and vaccines business.
The company has faced stiff competition from local manufacturers and cheaper generic drugs from India. The big pharma will, however, retain its production facility in Nairobi’s Industrial area under its stand-alone consumer healthcare affiliate Haleon.
About The Author
